GT Biopharma, Inc.
GTBP
$0.61
-$0.15-19.57%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 2.53M | 5.23M | 2.37M | 3.95M | 6.42M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 940.00K | 1.04M | 200.00K | 188.00K | 248.00K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 853.00K | 853.00K | 93.00K | 93.00K | 93.00K |
| Total Current Assets | 4.32M | 7.12M | 2.66M | 4.23M | 6.76M |
|
|
|||||
| Total Current Assets | 4.32M | 7.12M | 2.66M | 4.23M | 6.76M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 4.32M | 7.12M | 2.66M | 4.23M | 6.76M |
|
|
|||||
| Total Accounts Payable | 769.00K | 1.37M | 2.38M | 3.85M | 2.61M |
| Total Accrued Expenses | 400.00K | 608.00K | 1.13M | 1.80M | 1.87M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | 152.00K | 325.00K | 126.00K | 252.00K | 182.00K |
| Total Other Current Liabilities | 152.00K | 325.00K | 126.00K | 252.00K | 182.00K |
| Total Current Liabilities | 1.32M | 2.31M | 3.64M | 5.90M | 4.66M |
|
|
|||||
| Total Current Liabilities | 1.32M | 2.31M | 3.64M | 5.90M | 4.66M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 1.32M | 2.31M | 3.64M | 5.90M | 4.66M |
|
|
|||||
| Common Stock & APIC | 703.78M | 700.38M | 695.02M | 693.56M | 693.55M |
| Retained Earnings | -700.78M | -697.52M | -696.00M | -695.23M | -691.45M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 3.00M | 2.86M | -981.00K | -1.67M | 2.10M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 1.00K | 1.96M | 1.00K | 1.00K | 1.00K |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 1.00K | 1.96M | 1.00K | 1.00K | 1.00K |
|
|
|||||
| Total Common Equity | 3.00M | 2.86M | -981.00K | -1.67M | 2.10M |
| Total Preferred Equity | 1.00K | 1.96M | 1.00K | 1.00K | 1.00K |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 3.00M | 4.82M | -980.00K | -1.67M | 2.10M |
|
|
|||||